What treatment in 2017 for inoperable pancreatic cancers?

J Taieb, AL Pointet, JL Van Laethem, B Laquente, S Pernot, F Lordick, M Reni

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Original languageEnglish
Pages (from-to)1473-1483
Number of pages11
JournalAnnals of oncology : official journal of the European Society for Medical Oncology
Volume28
Issue number7
DOIs
Publication statusPublished - 2017

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
gemcitabine
Therapeutics
Standard of Care
Radiotherapy
Survival
Research
Pancreatic Carcinoma
Neoplasms

Cite this

What treatment in 2017 for inoperable pancreatic cancers? / Taieb, J; Pointet, AL; Van Laethem, JL; Laquente, B; Pernot, S; Lordick, F; Reni, M.

In: Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, No. 7, 2017, p. 1473-1483.

Research output: Contribution to journalArticle

Taieb, J ; Pointet, AL ; Van Laethem, JL ; Laquente, B ; Pernot, S ; Lordick, F ; Reni, M. / What treatment in 2017 for inoperable pancreatic cancers?. In: Annals of oncology : official journal of the European Society for Medical Oncology. 2017 ; Vol. 28, No. 7. pp. 1473-1483.
@article{f9f1762e1daf41a1aa9027e82b2ceae4,
title = "What treatment in 2017 for inoperable pancreatic cancers?",
abstract = "Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future. {\^A}{\circledC} The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.",
author = "J Taieb and AL Pointet and {Van Laethem}, JL and B Laquente and S Pernot and F Lordick and M Reni",
year = "2017",
doi = "10.1093/annonc/mdx174",
language = "English",
volume = "28",
pages = "1473--1483",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "7",

}

TY - JOUR

T1 - What treatment in 2017 for inoperable pancreatic cancers?

AU - Taieb, J

AU - Pointet, AL

AU - Van Laethem, JL

AU - Laquente, B

AU - Pernot, S

AU - Lordick, F

AU - Reni, M

PY - 2017

Y1 - 2017

N2 - Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

AB - Pancreatic adenocarcinoma is a frequent and severe disease, either diagnosed as metastatic pancreatic adenocarcinoma (MPA) or as locally advanced pancreatic carcinoma (LAPC). Though no improvement in patients outcome have been made between 1996 and 2011, since 5 years new treatment options have become available to treat our patients. New standard first line regimens, such as FOLFIRINOX and gemcitabine combined with nab-paclitaxel, have improved overall survivals and second line treatments have been tested and validated. Other first-line treatments have failed, but research remains active and trials are ongoing with promising new anti-cancer agents. These new effective regimens used for MPA have yielded promising results in LAPC patients in open cohorts or phase II trials and a recent trial have failed to demonstrate the added value of classical external radiotherapy in this setting. Here, we review current standards of care in LAPC and MPA, consider the latest challenges and strategic questions, and examine what we may hope for in the future. © The Author 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

U2 - 10.1093/annonc/mdx174

DO - 10.1093/annonc/mdx174

M3 - Article

VL - 28

SP - 1473

EP - 1483

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 7

ER -